Lst JJ: Secretion on the incretin hormones glucagon-like peptide-1 and gastric

May 9, 2024

Lst JJ: Secretion from the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in regular man throughout the day. Scand J Gastroenterol 1996, 31:66570.Conclusion Overall, our study investigated the response of fasting GLP-1 concentration to a 7-day overfeeding protocol inWadden et al. Nutrition Metabolism 2013, 10:33 http://www.nutritionandmetabolism/content/10/1/Page eight of4.five.six.7.eight. 18. T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ: Incretin secretion in relation to meal size and physique weight in healthier subjects and individuals with variety 1 and form 2 diabetes mellitus. J Clin Endocrinol Metab 2003, 88:2706713. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is definitely a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:95257. Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(76) amide is transformed to glucagon-like peptide-1-(96)amide by dipeptidyl peptidase IV inside the capillaries supplying the L cells with the porcine intestine. Endocrinology 1999, 140:5356363. Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA: Suppression of glucagon secretion is lower after oral glucose administration than for the duration of intravenous glucose administration in human subjects. Diabetologia 2007, 50:80613. Kazakos KA, Sarafidis PA, Yovos JG: The effect of diabetic autonomic neuropathy on the incretin effect. Med Sci Monit 2008, 14:CR213 R220. Orskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(7807) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123:2009013. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(76) amide in variety I diabetic sufferers.AS-85 Description Diabetes Care 1996, 19:58086.BMS-986278 medchemexpress de Heer J, Rasmussen C, Coy DH, Holst JJ: Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion by means of somatostatin (receptor subtype 2) inside the perfused rat pancreas.PMID:35901518 Diabetologia 2008, 51:2263270. Larsen PJ, Vrang N, Tang-Christensen M: Central pre-proglucagon derived peptides: opportunities for therapy of obesity. Curr Pharm Des 2003, 9:1373382. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM: Power intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese guys. Int J Obes Relat Metab Disord 1999, 23:30411. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses power intake in humans. J Clin Invest 1998, 101:51520. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthier humans. Am J Physiol 1997, 273:E981 988. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993, 38:66573. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Decreased incretin impact in sort two (non-insulin-dependent) diabetes. Diabetologia 1986, 29:462. Holst JJ: Therapy of kind two diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002, 18:4.